🔗 Share this article

A shadow market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Acquiring Popularity Online

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Viewers are encouraged to message these profiles directly for source information, while also receiving promotional offers.

Active Commerce on Messaging Platforms

Additionally, a flourishing market exists on messaging services, where groups with numerous of members share comparison photos, injection guides and claims of next-day British shipping. Sellers market the drug there before redirecting buyers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the successor to Ozempic.

Healthcare Professionals Express Concerns

However, doctors and pharmacists have warned that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering substances of unknown origin.

Some experts said the popularity for the experimental drug could be connected to the rising cost of approved slimming treatments such as Mounjaro.

Legal Position and Enforcement

Selling retatrutide on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some content creators try to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, marketing, and consumer laws, risking fines, legal action or prison.

Service Response and Content Removal

According to the social media company, the service has taken down violative material and banned related keywords and query recommendations. The company stated it was committed to maintaining the service secure and allocating resources in enhancing enforcement strategies.

Online Marketplace Operations

Investigations also discovered communities with up to 9,000 members marketing retatrutide using the platform's integrated discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with thousands of members, populated with images of slimming results, positive testimonials and step-by-step guides for mixing or administering at residence.

Within minutes of entering one group, a seller shared contact information, where the majority of purchases occur. The seller sent an instruction manual and guaranteed shipping within two days. When asked whether the product was authentic, one seller responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. None inquired about weight, health issues or past usage.

Item Information and Costs

Inside these groups, posts display dark colored parcels with postal service labels, claiming to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at residence with purified liquid, or ready-to-use injectors typically sold at £160 for 20 milligrams. When asked how long a pen should last, sellers give conflicting responses ranging from a several days to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for the messaging service said it actively monitored harmful content on its service including content that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are administering substances they cannot confirm. Even if the research behind this drug is valid, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the increase in interest to current price rises for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the environment they were made in was sterile,” she explained.

Her staff has already encountered individuals harmed by self-injection from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated the substance was in third stage clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a company investigational substance not yet authorized … may subject patients to potentially serious health risks”.